Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912372491> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2912372491 endingPage "675" @default.
- W2912372491 startingPage "675" @default.
- W2912372491 abstract "In an analysis from the second year of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT), Sharma et al (p. 865) described the association between visual acuity (VA) and morphologic features on fundus photography (FP), fluorescein angiography (FA), and optical coherence tomography (OCT). They found that the associations between VA and morphologic features that were identified during year 1 of this prospective, randomized study were maintained or strengthened during year 2. After 2 years of intravitreal therapy, the worst visual acuity was seen in eyes with residual intraretinal fluid in the foveal center, abnormally thin retinas, a thicker subretinal tissue complex, as seen on OCT, or subfoveal geographic atrophy or scarring, as noted on FP/FA. In contrast, the presence of subretinal fluid in the foveal center was associated with better VA. Of the 1185 CATT participants, 993 (84%) had fluid on OCT at baseline and completed 2 years of follow-up. When it comes to intravitreal injections for age-related macular degeneration (AMD), how much of a treatment burden are patients willing to accept in exchange for potential improvements in vision? In a discrete choice interview study conducted in Germany, Mueller et al (p. 876) assessed patients’ attitudes via a series of telephone interviews designed to measure their preferences regarding treatment schemes and time needed for each appointment. All told, 284 patients with AMD completed the interviews. They indicated that visual acuity (VA) gains were their highest priority, even if that meant experiencing a higher treatment burden (such as monthly eye exams and intravitreal injections every 4 or 8 weeks) and more time traveling to the physician’s office or waiting to see the physician. This finding held true in all subgroups stratified by gender, age, current VA, and length of experience with intravitreal therapy. Diniz-Filho et al (p. 754) evaluated the association between rates of progressive visual field (VF) loss and symptoms of depression in glaucoma patients. They found that a faster rate of VF loss was associated with a greater incidence of depressive symptoms. For this prospective observational cohort study, the researchers enrolled 102 patients (204 eyes) with glaucomatous VF loss. Glaucoma progression was measured by standard automated perimetry (SAP), while symptoms of depression were assessed via the Geriatric Depression Scale (GDS) questionnaire. The patients were followed for an average of 2.2±0.6 years (range, 1.0 to 3.9 years). In the univariable model, each 1 decibel (dB) per year change in binocular SAP was associated with a change of 2.0 units in the GDS scores—and in the multivariable model, which adjusted for factors such as age, gender, and race, each 1 dB/year change in binocular SAP was associated with a change of 3.0 units in the GDS scores. De Moraes et al (p. 744) calculated whether a 24-hour recording of intraocular pressure (IOP) measurements taken by a wireless contact lens sensor (CLS) could be correlated with the rate of visual field (VF) progression in treated glaucomatous eyes. They found that a combination of CLS parameters obtained during a single session provided a signature that appears to explain the rate of VF progression better than summary of office-hour IOP measurements taken in multiple visits. For this prospective cross-sectional study, the researchers evaluated 40 patients (40 eyes) who were being treated for glaucoma and had undergone 8 or more 24-2 VF tests. The CLS parameters are derived from changes in volume and elasticity in ocular tissues, and 2 of the parameters—the number of long peaks and mean peak ratio when patients were awake—were the best predictors of faster progression, the researchers found. Moreover, the CLS parameters provided better measures of goodness-of-fit than did Goldmann IOP parameters (mean, peak, and fluctuation) in the same time period. Straatsma and Weeks (p. 908) set out to provide an overview of the remarkable and multifaceted achievements of Jules Stein, MD. Using both published and unpublished biographical material, they described Dr. Stein’s early interests in medicine, music, and business—and they traced the ways in which those fledgling interests developed and wove together throughout his life, from his early career in ophthalmology to his tenure as a pioneering entertainment mogul and his substantial philanthropic work. The latter included the founding of Research to Prevent Blindness, the origin of what is now known as the Stein Eye Institute in Los Angeles, and a successful campaign to establish the National Eye Institute as a separate entity within the National Institutes of Health." @default.
- W2912372491 created "2019-02-21" @default.
- W2912372491 creator A5063127178 @default.
- W2912372491 date "2016-04-01" @default.
- W2912372491 modified "2023-09-25" @default.
- W2912372491 title "This Issue at a Glance" @default.
- W2912372491 doi "https://doi.org/10.1016/j.ophtha.2016.02.011" @default.
- W2912372491 hasPublicationYear "2016" @default.
- W2912372491 type Work @default.
- W2912372491 sameAs 2912372491 @default.
- W2912372491 citedByCount "0" @default.
- W2912372491 crossrefType "journal-article" @default.
- W2912372491 hasAuthorship W2912372491A5063127178 @default.
- W2912372491 hasBestOaLocation W29123724911 @default.
- W2912372491 hasConcept C118487528 @default.
- W2912372491 hasConcept C119767625 @default.
- W2912372491 hasConcept C141071460 @default.
- W2912372491 hasConcept C168563851 @default.
- W2912372491 hasConcept C188816634 @default.
- W2912372491 hasConcept C2776391266 @default.
- W2912372491 hasConcept C2776403814 @default.
- W2912372491 hasConcept C2776474195 @default.
- W2912372491 hasConcept C2778257484 @default.
- W2912372491 hasConcept C2778818243 @default.
- W2912372491 hasConcept C2779100554 @default.
- W2912372491 hasConcept C2780248432 @default.
- W2912372491 hasConcept C2780827179 @default.
- W2912372491 hasConcept C30181142 @default.
- W2912372491 hasConcept C71924100 @default.
- W2912372491 hasConceptScore W2912372491C118487528 @default.
- W2912372491 hasConceptScore W2912372491C119767625 @default.
- W2912372491 hasConceptScore W2912372491C141071460 @default.
- W2912372491 hasConceptScore W2912372491C168563851 @default.
- W2912372491 hasConceptScore W2912372491C188816634 @default.
- W2912372491 hasConceptScore W2912372491C2776391266 @default.
- W2912372491 hasConceptScore W2912372491C2776403814 @default.
- W2912372491 hasConceptScore W2912372491C2776474195 @default.
- W2912372491 hasConceptScore W2912372491C2778257484 @default.
- W2912372491 hasConceptScore W2912372491C2778818243 @default.
- W2912372491 hasConceptScore W2912372491C2779100554 @default.
- W2912372491 hasConceptScore W2912372491C2780248432 @default.
- W2912372491 hasConceptScore W2912372491C2780827179 @default.
- W2912372491 hasConceptScore W2912372491C30181142 @default.
- W2912372491 hasConceptScore W2912372491C71924100 @default.
- W2912372491 hasIssue "4" @default.
- W2912372491 hasLocation W29123724911 @default.
- W2912372491 hasOpenAccess W2912372491 @default.
- W2912372491 hasPrimaryLocation W29123724911 @default.
- W2912372491 hasRelatedWork W1523731927 @default.
- W2912372491 hasRelatedWork W1996187756 @default.
- W2912372491 hasRelatedWork W2040487770 @default.
- W2912372491 hasRelatedWork W2074575505 @default.
- W2912372491 hasRelatedWork W2080584386 @default.
- W2912372491 hasRelatedWork W2084438553 @default.
- W2912372491 hasRelatedWork W2099433064 @default.
- W2912372491 hasRelatedWork W3031001655 @default.
- W2912372491 hasRelatedWork W3131645009 @default.
- W2912372491 hasRelatedWork W3204950947 @default.
- W2912372491 hasVolume "123" @default.
- W2912372491 isParatext "false" @default.
- W2912372491 isRetracted "false" @default.
- W2912372491 magId "2912372491" @default.
- W2912372491 workType "article" @default.